How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding of) Hypertension Therapy.

Stephanie W Watts, Raymond R Townsend, Richard R Neubig

Open access · hybridAbstract readReview

In one paragraph

Review in American journal of hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 35% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.CNS spectrums · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Stephanie W WattsDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan 48824-131, USA.ORCID 0000-0002-9653-6357

Raymond R TownsendDepartment of Nephrology and Hypertension, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.

Richard R NeubigDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan 48824-131, USA.

Michigan State University · USUniversity of Pennsylvania · US

Funding

The perivascular adipocyte: integrating mechanical and structural cues into vasoactive functionP01HL152951 · NHLBI · MICHIGAN STATE UNIVERSITY · 2022 to 2025

$21.2M

NHLBI NIH HHS P01 HL152951

6 · The paper itself

Abstract

backgroundMany hypertension therapeutics were developed prior to major advances in drug receptor theory. Moreover, newer drugs may take advantage of some of the newly understood modalities of receptor function. GOAL: The goal of this review is to provide an up-to-date summary of drug receptor theory. This is followed by a discussion of the drug classes recognized for treating hypertension to which new concepts in receptor theory apply.

resultsWe raise ideas for mechanisms of potential new antihypertensive drugs and whether they may take advantage of new theories in drug-receptor interaction.

Indexed as

HypertensionAntihypertensive AgentsDrug InteractionsHumansReceptors, DrugAntihypertensive AgentsReceptors, Drugagonistantagonistblood pressureconstitutive activitydrug–receptor interactiondrug receptor theoryhypertensioninverse agonist

Identifiers

PMID38150382

DOI10.1093/ajh/hpad121

PMCPMC10941088

OpenAlexW4390262760

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.